Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
06/10/2021 - 08:00 AM
BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the virtual JMP Securities Life Sciences Conference taking place June 16 – 17, 2021.
Event: The JMP Securities Life Sciences Conference Date: Thursday, June 17 Fireside Chat Time: 2:30 p.m. ET
Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com . A replay of the fireside chat will be archived on the website and available for approximately 90 days following the live event.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/ .
Follow us on Twitter @ViridianThera and on LinkedIn.
Viridian Contacts: Investors: IR@viridiantherapeutics.com
Media: PR@viridiantherapeutics.com
Viridian Therapeutics Inc
VRDN Rankings
#4219 Ranked by Stock Gains
VRDN Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Country
US
City
Boulder
About VRDN
miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research
